Tokyo Tape
Sign in
← OncoTherapy Science

Half-year report · Q2

4564.TEDINET S100UOSE
Period2024-04-01 → 2024-09-30
Filed2024-11-11
StandardJapan GAAP
ConsolidatedYes
Data checks12 of 12 passed
Key figures · 42
MetricValuePeriodScopeSource row
Revenue¥225m2024-04-01 → 2024-09-30Cons.Net sales
Revenue¥356m2023-04-01 → 2023-09-30Cons.Net sales
Operating income−¥531m2024-04-01 → 2024-09-30Cons.Operating income
Operating income−¥695m2023-04-01 → 2023-09-30Cons.Operating income
Ordinary income−¥545m2024-04-01 → 2024-09-30Cons.Ordinary income
Ordinary income−¥1.1bn2023-04-01 → 2024-03-31Cons.Ordinary income loss (5-year summary)
Ordinary income−¥708m2023-04-01 → 2023-09-30Cons.Ordinary income
Profit before tax−¥545m2024-04-01 → 2024-09-30Cons.Income before income taxes
Profit before tax−¥709m2023-04-01 → 2023-09-30Cons.Income before income taxes
Net income (owners)−¥546m2024-04-01 → 2024-09-30Cons.Profit loss attributable to owners of parent
Net income (owners)−¥1.3bn2023-04-01 → 2024-03-31Cons.Profit loss attributable to owners of parent (5-year summary)
Net income (owners)−¥711m2023-04-01 → 2023-09-30Cons.Profit loss attributable to owners of parent
Net income−¥546m2024-04-01 → 2024-09-30Cons.Profit loss
Net income−¥711m2023-04-01 → 2023-09-30Cons.Profit loss
Total assets¥1.5bnat 2024-09-30Cons.Assets
Total assets¥867mat 2024-03-31Cons.Assets
Total assets¥1.2bnat 2023-09-30Cons.Total assets (5-year summary)
Total liabilities¥548mat 2024-09-30Cons.Liabilities
Total liabilities¥514mat 2024-03-31Cons.Liabilities
Net assets / equity¥1.0bnat 2024-09-30Cons.Net assets
Net assets / equity¥354mat 2024-03-31Cons.Net assets
Net assets / equity¥935mat 2023-09-30Cons.Net assets (5-year summary)
Cash and deposits¥1.1bnat 2024-09-30Cons.Cash and deposits
Cash and deposits¥528mat 2024-03-31Cons.Cash and deposits
Cash & equivalents¥1.1bnat 2024-09-30Cons.Cash and cash equivalents
Cash & equivalents¥528mat 2024-03-31Cons.Cash and cash equivalents
Cash & equivalents¥881mat 2023-09-30Cons.Cash and cash equivalents
Cash & equivalents¥1.1bnat 2023-03-31dCons.Cash and cash equivalents
Operating cash flow−¥579m2024-04-01 → 2024-09-30Cons.Net cash provided by used in operating activities
Operating cash flow−¥1.2bn2023-04-01 → 2024-03-31Cons.Net cash provided by used in operating activities (5-year summary)
Operating cash flow−¥880m2023-04-01 → 2023-09-30Cons.Net cash provided by used in operating activities
Investing cash flow−¥33m2023-04-01 → 2024-03-31Cons.Net cash provided by used in investing activities (5-year summary)
Investing cash flow−¥34m2023-04-01 → 2023-09-30Cons.Net cash provided by used in investment activities
Financing cash flow¥1.1bn2024-04-01 → 2024-09-30Cons.Net cash provided by used in financing activities
Financing cash flow¥671m2023-04-01 → 2024-03-31Cons.Net cash provided by used in financing activities (5-year summary)
Financing cash flow¥677m2023-04-01 → 2023-09-30Cons.Net cash provided by used in financing activities
EPS (basic)¥-2.182024-04-01 → 2024-09-30Cons.Basic earnings loss per share (5-year summary)
EPS (basic)¥-6.052023-04-01 → 2024-03-31Cons.Basic earnings loss per share (5-year summary)
EPS (basic)¥-3.422023-04-01 → 2023-09-30Cons.Basic earnings loss per share (5-year summary)
Equity ratio59.9%at 2024-09-30Cons.Equity to asset ratio (5-year summary)
Equity ratio32.2%at 2024-03-31Cons.Equity to asset ratio (5-year summary)
Equity ratio73.4%at 2023-09-30Cons.Equity to asset ratio (5-year summary)

Periods use the dates stated in the filing. d = earlier-year period dated by calendar; v = that date confirmed by the company's own earlier filing.

Segments · 28
SegmentItemPeriodValue
Reconciling Itemsreconcilingrevenue2024-04-01 → 2024-09-30−¥135,000
Reconciling Itemsreconcilingrevenue intersegment2024-04-01 → 2024-09-30−¥135,000
Reconciling Itemsreconcilingsegment profit2024-04-01 → 2024-09-30−¥178m
jpcrp040300-q2r_E05363-000Cancer Precision Medical Businessreportable segmentrevenue2024-04-01 → 2024-09-30¥222m
jpcrp040300-q2r_E05363-000Cancer Precision Medical Businessreportable segmentrevenue external2024-04-01 → 2024-09-30¥222m
jpcrp040300-q2r_E05363-000Cancer Precision Medical Businessreportable segmentsegment profit2024-04-01 → 2024-09-30−¥94m
jpcrp040300-q2r_E05363-000Research And Development Of Pharmaceutical Productsreportable segmentrevenue2024-04-01 → 2024-09-30¥3m
jpcrp040300-q2r_E05363-000Research And Development Of Pharmaceutical Productsreportable segmentrevenue external2024-04-01 → 2024-09-30¥3m
jpcrp040300-q2r_E05363-000Research And Development Of Pharmaceutical Productsreportable segmentrevenue intersegment2024-04-01 → 2024-09-30¥135,000
jpcrp040300-q2r_E05363-000Research And Development Of Pharmaceutical Productsreportable segmentsegment profit2024-04-01 → 2024-09-30−¥259m
—segment totalrevenue2024-04-01 → 2024-09-30¥225m
—segment totalrevenue external2024-04-01 → 2024-09-30¥225m
—segment totalrevenue intersegment2024-04-01 → 2024-09-30¥135,000
—segment totalsegment profit2024-04-01 → 2024-09-30−¥353m
Reconciling Itemsreconcilingrevenue2023-04-01 → 2023-09-30−¥149,000
Reconciling Itemsreconcilingrevenue intersegment2023-04-01 → 2023-09-30−¥149,000
Reconciling Itemsreconcilingsegment profit2023-04-01 → 2023-09-30−¥183m
jpcrp040300-q2r_E05363-000Cancer Precision Medical Businessreportable segmentrevenue2023-04-01 → 2023-09-30¥356m
jpcrp040300-q2r_E05363-000Cancer Precision Medical Businessreportable segmentrevenue external2023-04-01 → 2023-09-30¥356m
jpcrp040300-q2r_E05363-000Cancer Precision Medical Businessreportable segmentsegment profit2023-04-01 → 2023-09-30−¥109m
jpcrp040300-q2r_E05363-000Research And Development Of Pharmaceutical Productsreportable segmentrevenue2023-04-01 → 2023-09-30¥537,000
jpcrp040300-q2r_E05363-000Research And Development Of Pharmaceutical Productsreportable segmentrevenue external2023-04-01 → 2023-09-30¥387,000
jpcrp040300-q2r_E05363-000Research And Development Of Pharmaceutical Productsreportable segmentrevenue intersegment2023-04-01 → 2023-09-30¥149,000
jpcrp040300-q2r_E05363-000Research And Development Of Pharmaceutical Productsreportable segmentsegment profit2023-04-01 → 2023-09-30−¥403m
—segment totalrevenue2023-04-01 → 2023-09-30¥357m
—segment totalrevenue external2023-04-01 → 2023-09-30¥356m
—segment totalrevenue intersegment2023-04-01 → 2023-09-30¥149,000
—segment totalsegment profit2023-04-01 → 2023-09-30−¥512m

Segment names come from EDINET member IDs; not yet mapped to a common taxonomy.

All source rows · 411
ItemContextValueUnit
Selling general and administrative expensesPrior1YTDDuration200603000JPY
Selling general and administrative expensesCurrentYTDDuration204285000JPY
Business expensesPrior1YTDDuration1051212000JPY
Business expensesCurrentYTDDuration756201000JPY
Operating incomePrior1YTDDuration-694759000JPY
Operating incomeCurrentYTDDuration-531117000JPY
Foreign exchange gains noiPrior1YTDDuration－JPY
Foreign exchange gains noiCurrentYTDDuration1834000JPY
Other noiPrior1YTDDuration26000JPY
Other noiCurrentYTDDuration389000JPY
Non operating incomePrior1YTDDuration26000JPY
Non operating incomeCurrentYTDDuration2224000JPY
Interest expenses noePrior1YTDDuration－JPY
Interest expenses noeCurrentYTDDuration546000JPY
Stock issuance cost noePrior1YTDDuration8479000JPY
Stock issuance cost noeCurrentYTDDuration15729000JPY
Foreign exchange losses noePrior1YTDDuration4972000JPY
Foreign exchange losses noeCurrentYTDDuration－JPY
Non operating expensesPrior1YTDDuration13452000JPY
Non operating expensesCurrentYTDDuration16276000JPY
Ordinary incomePrior1YTDDuration-708185000JPY
Ordinary incomeCurrentYTDDuration-545169000JPY
Gain on reversal of subscription rights to shares eiPrior1YTDDuration1375000JPY
Gain on reversal of subscription rights to shares eiCurrentYTDDuration550000JPY
Extraordinary incomePrior1YTDDuration1375000JPY
Extraordinary incomeCurrentYTDDuration550000JPY
Impairment loss elPrior1YTDDuration2627000JPY
Impairment loss elCurrentYTDDuration－JPY
Extraordinary lossPrior1YTDDuration2627000JPY
Extraordinary lossCurrentYTDDuration－JPY
Income before income taxesPrior1YTDDuration-709438000JPY
Income before income taxesCurrentYTDDuration-544619000JPY
Income taxes currentPrior1YTDDuration1225000JPY
Income taxes currentCurrentYTDDuration1080000JPY
Income taxesPrior1YTDDuration1225000JPY
Income taxesCurrentYTDDuration1080000JPY
Profit lossPrior1YTDDuration-710663000JPY
Profit lossCurrentYTDDuration-545699000JPY
Profit loss attributable to owners of parentPrior1YTDDuration-710663000JPY
Profit loss attributable to owners of parentCurrentYTDDuration-545699000JPY
Profit lossPrior1YTDDuration-710663000JPY
Profit lossCurrentYTDDuration-545699000JPY
Comprehensive incomePrior1YTDDuration-710663000JPY
Comprehensive incomeCurrentYTDDuration-545699000JPY
Comprehensive income attributable to owners of the parentPrior1YTDDuration-710663000JPY
Comprehensive income attributable to owners of the parentCurrentYTDDuration-545699000JPY
Income before income taxesPrior1YTDDuration-709438000JPY
Income before income taxesCurrentYTDDuration-544619000JPY
Impairment loss ope cfPrior1YTDDuration2627000JPY
Impairment loss ope cfCurrentYTDDuration－JPY

Every row of the EDINET CSV. Item names are the XBRL element names; filed text is kept in its original Japanese. Filed text is available on Plus and Pro.

Data checks · 12 of 12 passed
balance sheet identityconsolidated 2024-03-31pass rounding
balance sheet identityconsolidated 2024-09-30pass rounding
dei present pass
period resolution pass
statement vs summary · net assetsconsolidated 2024-03-31pass
statement vs summary · net assetsconsolidated 2024-09-30pass
statement vs summary · net income attributable to parentconsolidated 2023-04-01/2023-09-30pass
statement vs summary · net income attributable to parentconsolidated 2024-04-01/2024-09-30pass
statement vs summary · operating cash flowconsolidated 2023-04-01/2023-09-30pass
statement vs summary · operating cash flowconsolidated 2024-04-01/2024-09-30pass
statement vs summary · total assetsconsolidated 2024-03-31pass
statement vs summary · total assetsconsolidated 2024-09-30pass